PDSB - PDS Biotechnology GAAP EPS of -$0.20 beats by $0.08

• PDS Biotechnology press release ( NASDAQ: PDSB ): Q2 GAAP EPS of -$0.20 beats by $0.08 .
• Cash balance as of June 30, 2022 was approximately $53M.
• “We made tremendous progress this quarter with our lead candidate, PDS0101, across all four ongoing Phase 2 clinical trials, and also with our advancing oncology pipeline candidates PDS0102 and PDS0103,” stated Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech. “Our clinical data at this year’s ASCO meeting not only solidified our confidence in our Versamune™ platform, but also in the potential of PDS0101 to make a meaningful difference in the treatment of advanced HPV16-positive cancer patients with significant unmet needs. With these data, we are hopeful that our upcoming meetings with the FDA will clarify our regulatory path forward for PDS0101.”

For further details see: